Opposing effect of amniotic membrane on angiogenesis originating from amniotic epithelial cells  by Niknejad, Hassan & Yazdanpanah, Ghasem
Journal of Medical Hypotheses and Ideas (2014) 8, 39–41Available online at www.sciencedirect.com
Journal of Medical Hypotheses and Ideas
journal homepage: www.elsevier.com/locate/jmhiREGULAR ARTICLEOpposing eﬀect of amniotic membrane on
angiogenesis originating from amniotic epithelial
cells* Corresponding author. Address: Nanomedicine and Tissue Engineering Research Center, Taleghani Hospital, Velenjak, P.O. Box 1985
Tehran, Iran. Tel.: +98 21 22439847; fax: +98 21 22439848.
E-mail address: niknejad@sbmu.ac.ir (H. Niknejad).
2251-7294 ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.
URL: www.tums.ac.ir/english/
doi:http://dx.doi.org/10.1016/j.jmhi.2013.08.002
Open access under CC BY-NC-ND
Open access under CC BY-NC-ND license.Hassan Niknejad a,*, Ghasem Yazdanpanah a,ba Nanomedicine and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
b Students’ Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, IranReceived 28 May 2013; revised 8 August 2013; accepted 11 August 2013
Available online 17 August 2013KEYWORDS
Angiogenesis;
Amniotic membrane;
Epithelial cellsAbstract There are controversies about the effects of amniotic membrane (AM) on angiogenesis.
It was recently hypothesised that denuded AM (without epithelial cells) can induce angiogenesis.
The results from the dorsal skinfold chamber method in an animal model and aortic ring assay
showed that the epithelial side of the AM inhibits vessel sprouting and reduces capillary numbers,
while the mesenchymal side of the AM increases angiogenesis. These data answered the controver-
sies about the angiogenic capability of the AM and raised some questions about the mechanisms by
which the AM affects angiogenesis. In this article, mechanism(s) by which the AM affects angiogen-
esis and viability state of amniotic cells and its effect on angiogenesis have been propounded.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd. license.Introduction
Regarding the article entitled ‘Inducing of angiogenesis is the
net effect of the amniotic membrane without epithelial cells’
published in J Med Hypotheses Ideas [1], we previously de-
scribed that controversial reports on angiogenesis of the amni-
otic membrane (AM) is due to its epithelial cells. Amniotic
epithelial cells express some anti-angiogenic substances includ-
ing thrombospondin-1, endostatin and heparin sulphateproteoglycan. In addition, all four tissue inhibitors of metallo-
proteases (TIMP-1, -2, -3 and -4), which have a potent anti-
angiogenic effect, are found in the AM [2]. Now, we have
tested this hypothesis and our results have been published in
the journal Placenta [3].
Carrying out an evaluation using the aortic ring assay and
microvital microscopy in rat, we found that the AM without
amniotic epithelial cells can promote angiogenesis. The angio-
genic effect of the AM was side dependent and the711151,
Figure 1 Opposing effects of amniotic membrane components on angiogenesis.
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genesis (Fig. 1). These promising results support our hypothe-
sis and can be an answer to the controversial reports on
angiogenesis of the AM.
Hypotheses
What is more important here is that the mentioned results
raised some questions about the mechanisms by which the
AM affects angiogenesis. In the aortic ring assay, we observed
that amniotic epithelial cells could inhibit cell growth and cap-
illary formation through cell–cell contact with endothelial
cells. This was explainable since epithelial cells inhibit prolifer-
ation and migration of endothelial cells through the inhibition
of endothelial cell attachment. However, what was problem-
atic was that the presence of epithelial cells suppressed angio-
genesis in the other side of the AM (mesenchymal side). These
data suggest the role of anti-angiogenic soluble factors secreted
from epithelial cells. This idea is supported by some studies
that demonstrated that some anti-angiogenic factors are
released from amniotic epithelial cells. Interleukin (IL)-1
receptor antagonist, TIMP3 and TIMP4 are some of these
anti-angiogenic factors [2]. By contrast, it has been reported
that amniotic epithelial cells secrete some angiogenic factors,
such as vascular endothelial growth factor (VEGF), IL-8,
angiogenin, interferon-c, IL-6, basic ﬁbroblast growth factor
(bFGF), epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF) [4,5]. Based on these data, amniotic epi-
thelial cells can possess both angiogenic and anti-angiogenic
properties. It seems that there are unknown and more effective
angiogenic or anti-angiogenic factors; hence, more studies are
needed to determine the anti-angiogenic mechanism of the
AM.
The second question is if the amnion cells are viable in the
transplanted amnion. This is a very important issue and needs
to be evaluated. If the amnion cells are not viable and do not
secrete biological substances, what would be the mechanistic
explanations for the differences in the angiogenic properties
depending on the sides of the amnion?
Evaluation of hypothesis
To evaluate the exact role of amniotic epithelial and mesenchy-
mal cells on angiogenesis, rat aortic ring assay could be used.
In this method, rat aorta would be cultured in Matrigel-
coated cell culture plate in standard media. Normally after afew days, aortic ring endothelial cells are observed to sprout
in the Matrigel, which demonstrates angiogenesis. To evalu-
ate the effects of AM cells, a conditioned medium of extracted
and cultured cells could be added to the aortic ring assay med-
ium and the number and/or length of developed capillaries
could be compared with control samples. The angiogenic
and anti-angiogenic factors in condition medium of the amni-
otic cells could be measured by enzyme-linked immunosorbent
assay (ELISA). The expression of these factors in the cells in
the gene and protein levels could also be evaluated by real-time
polymerase chain reaction (PCR) or Western blotting. More-
over, angiogenesis of two surfaces of the AM could be evalu-
ated using the dorsal skinfold chamber method in an animal
model, as described previously [3].
Discussion
The angiogenic property of AM has a vast application in
ischaemic organs, and also the anti-angiogenic characteristic
of AM makes it suitable for use as a tumour growth and
metastasis inhibitor. Therefore, the role of each component
of AM in angiogenesis and the underlying mechanisms should
be investigated to make it applicable in clinical situations.
The rationale behind the use of the AM is based on the fact
that the factors released by the amniotic cells [6] are involved
in the inducing or inhibition of angiogenesis. Therefore, the
AM could act by releasing the soluble factors that are embed-
ded within it and which have been secreted by the amniotic epi-
thelial cells while they were still alive. However, some
properties of the amnion are not dependent on cell viability.
For example, it has been shown that the presence of amniotic
epithelium (without viability) can inhibit attachment and culti-
vation of endothelial cells and decrease angiogenesis [7]. In
addition, there are several factors in the amniotic matrix that
can interfere with the process of angiogenesis. For example,
it has been shown that a covalent complex containing high-
molecular-weight hyaluronan in the extracellular matrix of
the AM inhibits angiogenesis [8]. This supports the notion that
the human AM seems to function not only by virtue of its
functional cells but also as a matrix and as a source of bioac-
tive soluble factors. So, the fact of which compartment of the
AM (epithelial cells (viable or not), mesenchymal cells and
some factors in the amniotic matrix) has the major role in
the inducing and inhibition of angiogenesis is an important is-
sue, which will be required to be investigated in future studies.
Also, since in vitro conditions do not exactly simulate in vivo
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mal models and in vivo situations.Overview Box
First Question: What do we already know about the
subject?
Amniotic membrane (AM) as a suitable candidate for tis-
sue engineering has different effects on angiogenesis. We
have previously hypothesized that controversial issues
about the angiogenesis of the AM originated from amni-
otic epithelial cells, and then our hypothesis was
approved; but still some questions remain to be
addressed.
Second Question: What does your proposed theory add to
the current knowledge available, and what beneﬁts does it
have?
We propose here that amniotic epithelial cells could inhi-
bit angiogenesis through both soluble factors and cell–cell
contact. We also demonstrate that the matrix of the AM
could have anti-angiogenic properties. Anti-angiogenic
properties of the AM could be used in situations such
as tumor cell growth and metastasis in which angiogenesis
is not suitable.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
A conditioned medium of amniotic epithelial cells could
be used in aortic ring assay using Matrigel to evaluate
the effects of epithelial cell soluble factors on angiogene-
sis. Moreover, angiogenesis of two surfaces of the AM
could be evaluated using the dorsal skinfold chamber
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